1. Home
  2. PAYS vs SLN Comparison

PAYS vs SLN Comparison

Compare PAYS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$5.92

Market Cap

293.4M

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.80

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYS
SLN
Founded
2001
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.4M
236.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PAYS
SLN
Price
$5.92
$5.80
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$9.42
$42.60
AVG Volume (30 Days)
1.2M
342.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
85.71
N/A
EPS
0.13
N/A
Revenue
$24,120,434.00
N/A
Revenue This Year
$34.33
N/A
Revenue Next Year
$14.64
N/A
P/E Ratio
$45.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.89
$1.97
52 Week High
$8.88
$7.91

Technical Indicators

Market Signals
Indicator
PAYS
SLN
Relative Strength Index (RSI) 81.25 51.95
Support Level $5.09 $5.79
Resistance Level $8.73 $6.19
Average True Range (ATR) 0.39 0.55
MACD 0.24 -0.06
Stochastic Oscillator 94.87 35.17

Price Performance

Historical Comparison
PAYS
SLN

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: